| scholarly article | Q13442814 |
| P50 | author | Shams Tabrez | Q38323793 |
| P2093 | author name string | Adel M Abuzenadah | |
| Ghazi A Damanhouri | |||
| Nigel H Greig | |||
| Mohammad A Kamal | |||
| Shazi Shakil | |||
| Qamre Alam | |||
| Nasimudeen R Jabir | |||
| P2860 | cites work | Tyrosine hydroxylase and regulation of dopamine synthesis | Q21710723 |
| Parkinson's disease, pesticides, and glutathione transferase polymorphisms | Q22004263 | ||
| Dopamine Mediates Context-Dependent Modulation of Sensory Plasticity in C. elegans | Q22251257 | ||
| Glucagon-like peptide analogues for type 2 diabetes mellitus | Q24235918 | ||
| A role for alpha-synuclein in the regulation of dopamine biosynthesis | Q24293727 | ||
| Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling | Q24313304 | ||
| Parkin is recruited selectively to impaired mitochondria and promotes their autophagy | Q24317471 | ||
| Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism | Q24321359 | ||
| GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons | Q24336322 | ||
| PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease | Q24597726 | ||
| Tyrosine hydroxylase as a target for deltamethrin in the nigrostriatal dopaminergic pathway | Q24630617 | ||
| Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease | Q24647189 | ||
| Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases | Q24648367 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| Glutamate and neurotrophic factors in neuronal plasticity and disease | Q24653626 | ||
| Crystal structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative diseases | Q27740782 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. | Q27863413 | ||
| Prospects for new restorative and neuroprotective treatments in Parkinson's disease | Q28138668 | ||
| alpha-Synuclein shares physical and functional homology with 14-3-3 proteins | Q28139698 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration | Q28237641 | ||
| Tyrosine hydroxylase and Parkinson's disease | Q28273702 | ||
| Tyrosine hydroxylase | Q28279680 | ||
| Dopaminergic neuron-specific oxidative stress caused by dopamine itself | Q28285905 | ||
| Biotechnology: Crossing the barrier | Q28291058 | ||
| The phylogeny of the aromatic amino acid hydroxylases revisited by characterizing phenylalanine hydroxylase from Dictyostelium discoideum | Q44498627 | ||
| Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection | Q44937132 | ||
| The prevalence of Parkinson's disease in an Arab population, Wadi Ara, Israel. | Q45153652 | ||
| Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations | Q45302799 | ||
| Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. | Q45756120 | ||
| Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. | Q45918637 | ||
| PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease | Q46107948 | ||
| Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment | Q46198761 | ||
| In vitro phosphorylation of bovine adrenal chromaffin cell tyrosine hydroxylase by endogenous protein kinases | Q46202705 | ||
| Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease | Q46456058 | ||
| Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of alpha1-adrenoceptors in the isolated rat heart. | Q46460126 | ||
| Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce l-dopa | Q46578408 | ||
| Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice | Q46624242 | ||
| Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease | Q46691979 | ||
| Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice. | Q46698423 | ||
| Estradiol increases tyrosine hydroxylase activity of the A15 nucleus dopaminergic neurons during long days in the ewe. | Q48135889 | ||
| Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes | Q48174573 | ||
| Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease | Q48198986 | ||
| The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins | Q48216713 | ||
| Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice | Q43083221 | ||
| The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. | Q43107113 | ||
| 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's disease | Q43111584 | ||
| Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase | Q43185222 | ||
| Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy | Q43269023 | ||
| Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine | Q43509401 | ||
| Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association | Q43612897 | ||
| Nitration and inactivation of tyrosine hydroxylase by peroxynitrite | Q43759048 | ||
| A new splicing variant for human tyrosine hydroxylase in the adrenal medulla | Q43767721 | ||
| Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain | Q44295080 | ||
| Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. | Q44442300 | ||
| Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice | Q44493207 | ||
| Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells | Q48224712 | ||
| Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss | Q48253717 | ||
| Biochemical pathophysiology of Parkinson's disease. | Q48258284 | ||
| Particle bombardment-mediated gene transfer and expression in rat brain tissues | Q48317110 | ||
| Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. | Q48388817 | ||
| Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra | Q48452025 | ||
| Mechanisms of MPTP toxicity | Q48456918 | ||
| Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture | Q48492176 | ||
| Changes in tyrosine hydroxylase mRNA levels in medullary A1 and A2 neurons and locus coeruleus following castration and estrogen replacement in rats | Q48502064 | ||
| Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. | Q48546607 | ||
| Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes | Q48766810 | ||
| Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity | Q49046577 | ||
| Association of the Alzheimer's gene SORL1 with hippocampal volume in young, healthy adults | Q49088676 | ||
| Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease | Q49153506 | ||
| The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. | Q51011184 | ||
| Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. | Q52299253 | ||
| Environmental antecedents of young-onset Parkinson's disease. | Q52543483 | ||
| Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. | Q53439907 | ||
| Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. | Q55044523 | ||
| Characterisation of novel splicing variants of the tyrosine hydroxylase C-terminal domain in human neuroblastic tumours | Q61761032 | ||
| Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. | Q64855052 | ||
| Activation and multiple-site phosphorylation of tyrosine hydroxylase in perfused rat adrenal glands | Q67512776 | ||
| Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year | Q68772556 | ||
| beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease | Q71631171 | ||
| Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application | Q72226093 | ||
| Parkinson's disease, environment and genes | Q77599271 | ||
| The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 | ||
| S100beta and fibroblast growth factor-2 are present in cultured Schwann cells and may exert paracrine actions on the peripheral nerve injury | Q82711679 | ||
| Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity | Q83409927 | ||
| Nonprofit disease groups earmark grants for drug repositioning | Q84911156 | ||
| Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases | Q36330960 | ||
| Physiological function and putative therapeutic impact of the FGF-2 system in peripheral nerve regeneration--lessons from in vivo studies in mice and rats. | Q36375506 | ||
| Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal | Q36455215 | ||
| Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines | Q36528609 | ||
| Novel pharmacological targets for the treatment of Parkinson's disease | Q36610996 | ||
| Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells | Q36700077 | ||
| The role of stem cells in Parkinson's disease | Q36716075 | ||
| Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease | Q36785396 | ||
| New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy | Q36803304 | ||
| The role of anti-inflammatory agents in Parkinson's disease | Q36938295 | ||
| Message in a bottle: long-range retrograde signaling in the nervous system | Q37009283 | ||
| Glutamate in dopamine neurons: synaptic versus diffuse transmission | Q37016446 | ||
| GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism | Q37078997 | ||
| Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α | Q37109350 | ||
| CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. | Q37121244 | ||
| Pharmacological enhancement of neuronal survival | Q37146138 | ||
| Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats | Q37162724 | ||
| Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element | Q37166339 | ||
| Paraquat and maneb induced neurotoxicity | Q37208604 | ||
| Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome | Q37319535 | ||
| Cell replacement therapy for Parkinson's disease | Q37325157 | ||
| Mendelian forms of Parkinson's disease | Q37376999 | ||
| Neuroprotective actions of sex steroids in Parkinson's disease | Q37467662 | ||
| Glutathione--a review on its role and significance in Parkinson's disease | Q37525862 | ||
| Inflammation in transgenic mouse models of neurodegenerative disorders | Q37626195 | ||
| Neurotrophic factor therapy for Parkinson’s disease | Q37796025 | ||
| The Role of GLP-1 in Neuronal Activity and Neurodegeneration | Q37811420 | ||
| GDNF and protection of adult central catecholaminergic neurons | Q37847791 | ||
| Oxidation chemistry of catecholamines and neuronal degeneration: an update | Q37861824 | ||
| Drug repositioning for orphan diseases | Q37866927 | ||
| Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? | Q37878285 | ||
| Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? | Q37886152 | ||
| A systematic review of the worldwide prevalence and incidence of Parkinson's disease. | Q37893133 | ||
| Genetic mutations and functions of PINK1. | Q37904442 | ||
| Allosteric regulation of phenylalanine hydroxylase | Q37946639 | ||
| What genetics tells us about the causes and mechanisms of Parkinson's disease | Q37947563 | ||
| Initial motor symptoms of Parkinson disease | Q37951820 | ||
| In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment | Q36299641 | ||
| Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development | Q36318080 | ||
| Behind the rosiglitazone controversy | Q37960108 | ||
| Novel GLP-1 receptor agonists for diabetes | Q37960149 | ||
| Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review | Q37964088 | ||
| Upcoming treatments in Parkinson's disease, including gene therapy | Q37968070 | ||
| Interactions between Egr1 and AP1 factors in regulation of tyrosine hydroxylase transcription | Q38356055 | ||
| Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells | Q38473449 | ||
| Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease | Q38493912 | ||
| Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease | Q39124093 | ||
| Tyrosine hydroxylase. Activation by protein phosphorylation and end product inhibition | Q39175516 | ||
| Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin | Q39382909 | ||
| Occupational exposures to metals as risk factors for Parkinson's disease | Q39441603 | ||
| Problems with long-term levodopa therapy for Parkinson's disease | Q39487689 | ||
| Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase | Q39508265 | ||
| Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice | Q39601884 | ||
| Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. | Q39615697 | ||
| Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum | Q39745332 | ||
| Expression of tyrosine hydroxylase increases the resistance of human neuroblastoma cells to oxidative insults. | Q39789685 | ||
| Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson's disease--a rat model study | Q39861102 | ||
| Absolute requirement of GDNF for adult catecholaminergic neuron survival | Q39974507 | ||
| 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture | Q40072661 | ||
| Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells | Q40097012 | ||
| Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene | Q40115210 | ||
| The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson's disease | Q40181263 | ||
| The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. | Q40227332 | ||
| Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 | ||
| Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells | Q40395753 | ||
| Long-term therapeutic effects on parkinsonian rats of intrastriatal co-grafts with genetically engineered fibroblasts expressing tyrosine hydroxylase and glial cell line-derived neurotrophic factor | Q40397682 | ||
| Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. | Q40519699 | ||
| A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells | Q40748616 | ||
| Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal | Q40758643 | ||
| Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ | Q40772649 | ||
| Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease | Q40861090 | ||
| Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model | Q40941898 | ||
| Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors | Q40988268 | ||
| Role of serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site- and phosphospecific antibodies and site-directed mutagenesis. | Q41006603 | ||
| Intricate regulation of tyrosine hydroxylase activity and gene expression | Q41078672 | ||
| Oxidative stress and antioxidant therapy in Parkinson's disease | Q41130535 | ||
| Oxidative stress and the pathogenesis of Parkinson's disease | Q41262986 | ||
| Epidemiologic study of Parkinson's disease in Hong Kong | Q41328143 | ||
| Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. | Q41573867 | ||
| Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease | Q41917715 | ||
| Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. | Q42057712 | ||
| Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). | Q42194018 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Neurotoxicity of the organochlorine insecticide heptachlor to murine striatal dopaminergic pathways | Q42502612 | ||
| Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. | Q42524942 | ||
| Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration | Q42685088 | ||
| Discovery of an antiparkinsonian drug: zonisamide | Q42726839 | ||
| Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease | Q43010410 | ||
| MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese | Q43073721 | ||
| Tyrosine hydroxylase phosphorylation: regulation and consequences | Q28295531 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo | Q28306009 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model | Q28344741 | ||
| Preventing levodopa-induced dyskinesias | Q28376608 | ||
| Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus | Q28573001 | ||
| Isoosmotic isolation of rat brain synaptic vesicles, some of which contain tyrosine hydroxylase | Q28582981 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 | ||
| A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease | Q30451794 | ||
| Is NADH effective in the treatment of Parkinson's disease? | Q30472795 | ||
| Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. | Q30476321 | ||
| Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines | Q30478476 | ||
| Localized striatal delivery of GDNF as a treatment for Parkinson disease | Q31038741 | ||
| The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety | Q32133943 | ||
| Raf-1 kinase and exoenzyme S interact with 14-3-3zeta through a common site involving lysine 49. | Q33292522 | ||
| Parkinson's disease: current and future challenges | Q33337881 | ||
| Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention | Q33663970 | ||
| The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen | Q33790013 | ||
| Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. | Q33832927 | ||
| Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis | Q33840243 | ||
| Molecular basis of levodopa-induced dyskinesias. | Q33890260 | ||
| The aromatic amino acid hydroxylases. | Q33900991 | ||
| Chaperone-like activity of synucleins | Q33903337 | ||
| Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. | Q33925878 | ||
| Structural Insight into the Aromatic Amino Acid Hydroxylases and Their Disease-Related Mutant Forms | Q33957484 | ||
| Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. | Q34010256 | ||
| Variability and validity of polymorphism association studies in Parkinson's disease | Q34011134 | ||
| Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells | Q34028497 | ||
| Approach to ex vivo gene therapy in the treatment of Parkinson's disease | Q34031071 | ||
| 14-3-3 proteins: regulation of subcellular localization by molecular interference | Q34127838 | ||
| Pharmacogenomics of neurodegenerative diseases | Q34137788 | ||
| Synucleinopathies: clinical and pathological implications | Q34140347 | ||
| Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants | Q34148293 | ||
| Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype | Q34158749 | ||
| GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. | Q34167980 | ||
| A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease | Q34209755 | ||
| Parkinson's disease--redox mechanisms | Q34263075 | ||
| Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature | Q34273182 | ||
| Dopamine neurons release transmitter via a flickering fusion pore | Q34301975 | ||
| Pesticides and risk of Parkinson disease: a population-based case-control study | Q34383364 | ||
| Recent advances in the genetics and pathogenesis of Parkinson disease | Q34502910 | ||
| Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California | Q34605203 | ||
| Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. | Q34646166 | ||
| Environmental factors in Parkinson's disease | Q34995010 | ||
| Catecholamine metabolism: an update on key biosynthetic enzymes and vesicular monoamine transporters | Q35001393 | ||
| Dopamine in crayfish and other crustaceans: distribution in the central nervous system and physiological functions | Q35050005 | ||
| The glucagon-like peptides: a double-edged therapeutic sword? | Q35181801 | ||
| The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys | Q35196195 | ||
| Gene therapy progress and prospects: Parkinson's disease | Q35206326 | ||
| Reactive oxygen species and the central nervous system | Q35389986 | ||
| Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells | Q35492403 | ||
| The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease | Q35552497 | ||
| The human tyrosine hydroxylase gene | Q35574200 | ||
| Insulin and neurodegenerative disease: shared and specific mechanisms | Q35674377 | ||
| Reactive oxygen species as mediators of signal transduction in ischemic preconditioning | Q35693492 | ||
| Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy | Q35748345 | ||
| Alpha-synuclein and the pathogenesis of Parkinson's disease | Q35795168 | ||
| Toxin models of mitochondrial dysfunction in Parkinson's disease. | Q35799141 | ||
| Could a loss of alpha-synuclein function put dopaminergic neurons at risk? | Q35800096 | ||
| The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression | Q36012226 | ||
| Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications | Q36102771 | ||
| Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders | Q36166654 | ||
| Structural changes in alpha-synuclein affect its chaperone-like activity in vitro | Q36281848 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 395-409 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | CNS and Neurological Disorders | Q15724632 |
| P1476 | title | A synopsis on the role of tyrosine hydroxylase in Parkinson's disease | |
| P478 | volume | 11 |
| Q90348452 | "New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction" |
| Q47891276 | A Single Neonatal Exposure to BMAA in a Rat Model Produces Neuropathology Consistent with Neurodegenerative Diseases |
| Q42173539 | An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism |
| Q34800195 | An overview on the correlation of neurological disorders with cardiovascular disease |
| Q38700215 | Beyond muscles: The untapped potential of creatine |
| Q38269376 | Cannabinoids: new promising agents in the treatment of neurological diseases |
| Q89452010 | Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum |
| Q64055243 | Effect of Majun Baladur on life span, climbing ability, oxidative stress and dopaminergic neurons in the transgenic model of Parkinson's disease |
| Q42178747 | Effects of Nogo-A Silencing on TNF-α and IL-6 Secretion and TH Downregulation in Lipopolysaccharide-Stimulated PC12 Cells |
| Q27304699 | Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. |
| Q33722420 | Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease |
| Q92051615 | Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases |
| Q37066046 | Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor |
| Q91722847 | Multigenerational metabolic profiling in the Michigan PBB registry |
| Q47905973 | Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects |
| Q35808114 | Neuroprotective Properties of the Standardized Extract from Camellia sinensis (Green Tea) and Its Main Bioactive Components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA Model of Parkinson's Disease. |
| Q58799123 | Palmitic Acid-Enriched Diet Increases α-Synuclein and Tyrosine Hydroxylase Expression Levels in the Mouse Brain |
| Q36154563 | Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease |
| Q90038947 | Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury |
| Q38854898 | Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss |
| Q38805550 | Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. |
| Q26771824 | The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress |
| Q33872721 | The Treadmill Exercise Protects against Dopaminergic Neuron Loss and Brain Oxidative Stress in Parkinsonian Rats. |
| Q30832756 | Tyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity. |
| Q60048467 | Unexpected Exacerbation of Neuroinflammatory Response After a Combined Therapy in Old Parkinsonian Mice |
| Q35623461 | Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties |
| Q89684847 | [Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder] |
Search more.